Supplementary Information

Virchows Archiv

Mucoepidermoid carcinoma of the salivary glands revisited with special reference to histologic grading and CRTCL3-MAML2 genotyping

André Fehr1#*, Sarah Werenicz2#, Pietro Trocchi3#, Markus Falk4, Reinhard E. Friedrich2, Angelika Stammler5, Andreas Stang3,6, Florian Oesterling6, Laura Khil6, Göran Stenman1, Werner Böcker7, Katharina Tiemann4, Andreas Stang3,6, Florian Oesterling6, Laura Khil6, Göran Stenman1, Werner Böcker7, Katharina Tiemann4, Thomas Löning7
# equal authorship

1 Sahlgrenska Center for Cancer Research, Department of Pathology, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden
2 Department of Oral and Craniomaxillofacial Surgery, Eppendorf University Hospital, University of Hamburg, Hamburg, Germany
3 Institute of Medical Informatics, Biometry and Epidemiology (IMIBE), University Hospital Essen, Essen, Germany
4 Institute for Hematopathology, Hamburg, Germany
5 Faculty of Medicine, Justus-Liebig-University Giessen, Giessen, Germany
6 Cancer Registry North Rhine-Westphalia, Bochum, Germany
7 Gerhard Seifert Reference-Center - Hansepathnet, Hamburg, Germany

* Corresponding author
André Fehr: andre.fehr@gu.se
**Supplementary Table**  Interobserver agreement of the grading (high- vs. low-) of 155 mucoepidermoid carcinomas between two pathologists according to potential modifiers of the agreement

|                        | AFIP Agreement (95%CI*) | Brandwein Agreement (95%CI) |
|------------------------|-------------------------|----------------------------|
|                        | Observed                | Weighted Kappa              | Observed                | Weighted Kappa              |
| **Overall (n=155)**    | 0.97 (0.93-0.99)        | 0.81 (0.65-0.97)            | 0.96 (0.92-0.99)        | 0.83 (0.71-0.96)            |
| **Age at diagnosis**   |                         |                            |                          |                            |
| (years)                |                         |                            |                          |                            |
| 0-49 (n=77)            | 0.99 (0.93-1.0)         | 0.66 (0.04-1.0)            | 0.99 (0.93-1.0)         | 0.79 (0.40-1.0)            |
| 50+ (n=78)             | 0.95 (0.87-0.99)        | 0.82 (0.66-0.99)            | 0.94 (0.86-0.98)        | 0.82 (0.67-0.97)            |
| **Stage**              |                         |                            |                          |                            |
| pT1 (n=108)            | 0.98 (0.93-1.0)         | 0.74 (0.39-1.0)            | 0.97 (0.92-0.99)        | 0.81 (0.60-1.0)            |
| >pT1 (n=47)            | 0.94 (0.82-0.99)        | 0.82 (0.61-1.0)            | 0.94 (0.82-0.99)        | 0.84 (0.66-1.0)            |
| **Anatomic Site**      |                         |                            |                          |                            |
| Major glands (n=69)    | 0.94 (0.86-0.98)        | 0.68 (0.39-0.97)            | 0.97 (0.90-1.0)         | 0.89 (0.74-1.0)            |
| Minor glands (n=86)    | 0.99 (0.94-1.0)         | 0.93 (0.79-1.0)            | 0.95 (0.89-0.99)        | 0.77 (0.56-0.99)            |
| **Gene Fusion**        |                         |                            |                          |                            |
| Positive (n=124)       | 0.99 (0.96-1.0)         | 0.88 (0.66-1.0)            | 0.98 (0.96-1.0)         | 0.83 (0.59-1.0)            |
| Negative (n=31)        | 0.87 (0.70-0.96)        | 0.71 (0.44-0.97)            | 0.87 (0.70-0.96)        | 0.74 (0.51-0.98)            |

* CI, confidence interval